Oral semaglutide superior in blood sugar reductions, weight-loss T2D adults
Findings presented Saturday from two Phase IIIa clinical trials evaluated oral semaglutide 14mg versus Jardiance (empagliflozin 25mg) in PIONEER 2 and oral semaglutide 14mg versus Victoza (liraglutide 1.8mg) in PIONEER 4 over 52 weeks in adults with type 2 diabetes (T2D).
Data from both trials were presented at the American Diabetes Association (ADA) 79th Scientific Sessions.
Danish diabetes care giant Novo Nordisk’s (NOV: N) oral semaglutide is an investigational once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill and does not currently have marketing authorization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze